Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer.

Waterhouse, David M; Espirito, Janet L; Chioda, Marc D; Baidoo, Bismark; Mardekian, Jack; Robert, Nicholas J; Masters, Elizabeth T

Waterhouse, David M; Espirito, Janet L; Chioda, Marc D; Baidoo, Bismark; Mardekian, Jack; Robert, Nicholas J; Masters, Elizabeth T.

Afiliación

Waterhouse DM; Oncology Hematology Care/The US Oncology Network, 5053 Wooster Rd, Cincinnati, OH, 45226, USA. david.waterhouse@usoncology.com.
Espirito JL; McKesson Life Sciences, 10101 Woodloch Forest, The Woodlands, TX, 77380, USA.
Chioda MD; Pfizer, Inc., 235 E 42nd St., New York, NY, 10017, USA.
Baidoo B; McKesson Life Sciences, 10101 Woodloch Forest, The Woodlands, TX, 77380, USA.
Mardekian J; Pfizer, Inc., 235 E 42nd St., New York, NY, 10017, USA.
Robert NJ; McKesson Life Sciences, 10101 Woodloch Forest, The Woodlands, TX, 77380, USA.
Masters ET; Pfizer, Inc., 235 E 42nd St., New York, NY, 10017, USA.

Drugs Real World Outcomes ; 7(4): 261-269, 2020 Dec.

Article en En | MEDLINE | ID: mdl-32725539

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Drugs Real World Outcomes Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google